Skip to search formSkip to main contentSkip to account menu

MK0626

Known as: MK-0626 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
AIMS Exercise capacity is reduced in heart failure (HF) patients, due mostly to skeletal muscle abnormalities including impaired… 
Highly Cited
2015
Highly Cited
2015
Dipeptidyl peptidase-4 (DPP4) inhibitors used for the treatment of type 2 diabetes are cardioprotective in preclinical studies… 
2015
2015
Objective— Intestinal overproduction of atherogenic chylomicron particles postprandially is an important component of diabetic… 
2015
2015
BackgroundGlucagon-like peptide 1 (GLP-1) analogs and dipeptidyl peptidase-4 (DPP4) inhibitors are a newer class of antidiabetics… 
2014
2014
Current treatment modalities for critical limb ischemia (CLI) are of limited benefit; therefore, advances in therapeutic… 
2014
2014
AIM To investigate the mechanism and in vivo effects of MK-0626, a dipeptidyl peptidase-4 inhibitor, on hepatic steatosis using… 
2014
2014
Individuals with type 2 diabetes (T2D) are at greater risk of bone fractures than those without diabetes. Certain oral diabetic… 
2014
2014
Background Tacrolimus (TAC)-induced pancreatic islet injury is one of the important causes of new-onset diabetes in transplant…